Skip to main content
Jinyu Bio-Technology Co.,Ltd. logo

Jinyu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 600201 ISIN · CNE000000Y37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,776 across all filing types
Latest filing 2023-05-09 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600201

About Jinyu Bio-Technology Co.,Ltd.

http://jinyubiotech.com/

Jinyu Bio-Technology Co., Ltd. focuses on the research, development, and manufacturing of veterinary biological products and pharmaceuticals. The company is a prominent supplier of animal vaccines, particularly specializing in Foot-and-Mouth Disease (FMD) vaccines, brucellosis vaccines, and solutions for swine and poultry diseases. It utilizes advanced biotechnology platforms, including large-scale suspension culture and high-efficiency purification processes, to produce high-titer, high-purity biologicals. The organization operates sophisticated research facilities and Biosafety Level 3 (P3) laboratories to support the development of diagnostic reagents and preventive treatments. Its operations center on enhancing animal health through scientific innovation, providing comprehensive disease control strategies for the global livestock industry and large-scale agricultural operations.

Recent filings

Filing Released Lang Actions
金宇生物技术股份有限公司监事会关于公司向特定对象发行A股股票相关事项的书面审核意见
Capital/Financing Update Classification · 95% confidence The document is a written supervisory board opinion regarding the company's issuance of A shares to specific investors. It references compliance with company law, securities law, and registration management measures, and discusses the legality, fairness, and feasibility of the share issuance plan. The document is a formal approval or opinion on a capital raising activity rather than a full financial report or announcement of voting results. It does not contain financial statements or earnings data, nor is it a simple announcement or certification. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2023-05-09 Chinese
金宇生物技术股份有限公司第十一届监事会第八次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a resolution from the Supervisory Board (监事会) of 金宇生物技术股份有限公司 regarding the company's plan to issue A shares to specific investors. It details the conditions, pricing, number of shares, use of proceeds, and other procedural matters related to a non-public issuance of shares. The document includes voting results on various proposals related to the issuance. It is not a financial report, earnings release, or audit report. It is a formal announcement of decisions made by the supervisory board concerning capital raising activities. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 4357 characters, which is sufficient to contain substantive content rather than a mere announcement of a report publication or a short notice. Hence, the classification is CAP with high confidence.
2023-05-09 Chinese
金宇生物技术股份有限公司关于召开2022年年度股东大会的通知
AGM Information Classification · 100% confidence The document is a notice about the convening of the 2022 Annual General Meeting (AGM) of 金宇生物技术股份有限公司, including details such as the date, voting methods, meeting agenda, and instructions for shareholders. It does not contain the actual annual report or financial statements but rather information about the meeting where such reports will be discussed and voted on. The document length is 3724 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2023-05-09 Chinese
金宇生物技术股份有限公司2023年度向特定对象发行A股股票募集资金运用可行性分析报告（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集资金运用的可行性分析报告（修订稿）" which translates to "Feasibility Analysis Report on the Use of Raised Funds (Revised)" for a specific issuance of A shares in 2023. It details the planned use of funds raised from a targeted share issuance, including investment projects, their necessity, feasibility, and expected economic benefits. The document is lengthy (over 13,000 characters) and contains detailed project descriptions, investment amounts, and strategic rationale. It is not a financial report like an annual or interim report, nor is it an announcement of voting results or a regulatory filing. It is a capital/financing update document focused on the use of proceeds from a share issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-05-09 Chinese
金宇生物技术股份有限公司关于公司对外担保情况的专项说明及独立意见
Regulatory Filings Classification · 95% confidence The document is a special statement and independent opinion by the independent directors regarding the company's external guarantees as of December 31, 2022. It references regulatory guidelines and confirms no external guarantees were made. The document is short (390 characters) and serves as a formal attestation or certification by independent directors rather than a full audit or financial report. It does not contain financial statements or detailed audit results but is a regulatory compliance statement. Therefore, it fits best under Regulatory Filings (RNS) as it is a compliance-related disclosure and independent opinion rather than a full Audit Report or Annual Report.
2023-04-21 Chinese
金宇生物技术股份有限公司信息披露管理制度（2023年4月修订）
Governance Information Classification · 95% confidence The document is a detailed internal management system for information disclosure of a company, specifying principles, responsibilities, procedures, and legal compliance related to disclosure of financial and other material information. It references various types of reports (annual, interim, quarterly) and regulatory requirements but does not itself contain any financial data, results, or actual report content. It is a governance and procedural document outlining how information disclosure should be managed and controlled within the company. Therefore, it fits best under Governance Information (CGR), which covers internal rules, board structure, and governance practices related to information disclosure.
2023-04-20 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.